MUM1/IRF4 mRNA表达作为多发性骨髓瘤患者的预后标志物 - Suppr

Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma.

作者信息

Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H, Drach J, Gaiger A, Jäger U, Ludwig H

出版信息

Leukemia. 2008 Feb;22(2):441-5. doi: 10.1038/sj.leu.2404895. Epub 2007 Aug 9.

DOI:10.1038/sj.leu.2404895

PMID:17690696

Abstract

摘要

相似文献

Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma.

Leukemia. 2008 Feb;22(2):441-5. doi: 10.1038/sj.leu.2404895. Epub 2007 Aug 9.

Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.

Anticancer Res. 2001 Jan-Feb;21(1B):633-8.

Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.

Vet Pathol. 2007 Nov;44(6):875-84. doi: 10.1354/vp.44-6-875.

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

Br J Haematol. 2011 Aug;154(3):325-36. doi: 10.1111/j.1365-2141.2011.08689.x. Epub 2011 Jun 24.

MUM1/IRF4: A Review.

Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):301-10. doi: 10.1097/PAI.0b013e3181cf1126.

Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.

Leukemia. 2005 Aug;19(8):1471-8. doi: 10.1038/sj.leu.2403833.

Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma.

Nat Genet. 1997 Oct;17(2):226-30. doi: 10.1038/ng1097-226.

A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma.

Br J Haematol. 2010 Aug;150(3):371-3. doi: 10.1111/j.1365-2141.2010.08199.x. Epub 2010 Apr 12.

Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.

Oncotarget. 2016 Jul 26;7(30):47127-47133. doi: 10.18632/oncotarget.9478.

Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia.

Leukemia. 2010 Apr;24(4):877-81. doi: 10.1038/leu.2009.298. Epub 2010 Jan 21.

引用本文的文献

Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma.

Res Sq. 2025 Apr 15:rs.3.rs-6306816. doi: 10.21203/rs.3.rs-6306816/v1.

Transcriptomic characterisation of acute myeloid leukemia cell lines bearing the same t(9;11) driver mutation reveals different molecular signatures.

BMC Genomics. 2025 Mar 25;26(1):300. doi: 10.1186/s12864-025-11415-1.

: the first rearrangement gene identified in TEMPI syndrome.

Haematologica. 2024 Aug 1;109(8):2701-2705. doi: 10.3324/haematol.2023.284727.

Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma.

Cells. 2023 Jan 3;12(1):196. doi: 10.3390/cells12010196.

The dynamic functions of IRF4 in B cell malignancies.

Clin Exp Med. 2023 Aug;23(4):1171-1180. doi: 10.1007/s10238-022-00968-0. Epub 2022 Dec 10.

Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance.

Turk J Haematol. 2022 Dec 1;39(4):245-253. doi: 10.4274/tjh.galenos.2022.2022.0046. Epub 2022 Aug 15.

Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.

STAR Protoc. 2021 May 27;2(2):100565. doi: 10.1016/j.xpro.2021.100565. eCollection 2021 Jun 18.

Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Front Genet. 2019 May 8;10:424. doi: 10.3389/fgene.2019.00424. eCollection 2019.

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.

Haematologica. 2014 Feb;99(2):e14-6. doi: 10.3324/haematol.2013.090142.

IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Med Oncol. 2013;30(2):594. doi: 10.1007/s12032-013-0594-8. Epub 2013 May 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献